Judy C Boughey1, Karla V Ballman2, Kelly K Hunt2, Linda M McCall2, Elizabeth A Mittendorf2, Gretchen M Ahrendt2, Lee G Wilke2, Huong T Le-Petross2. 1. Judy C. Boughey, Mayo Clinic; Karla V. Ballman, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Kelly K. Hunt, Elizabeth A. Mittendorf, and Huong T. Le-Petross, The University of Texas MD Anderson Cancer Center, Houston, TX; Linda M. McCall, Alliance Statistics and Data Center, Duke University, Durham, NC; Gretchen M. Ahrendt, University of Pittsburgh Cancer Institute, Pittsburgh, PA; and Lee G. Wilke, University of Wisconsin Hospital and Clinics, Madison, WI. boughey.judy@mayo.edu. 2. Judy C. Boughey, Mayo Clinic; Karla V. Ballman, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Kelly K. Hunt, Elizabeth A. Mittendorf, and Huong T. Le-Petross, The University of Texas MD Anderson Cancer Center, Houston, TX; Linda M. McCall, Alliance Statistics and Data Center, Duke University, Durham, NC; Gretchen M. Ahrendt, University of Pittsburgh Cancer Institute, Pittsburgh, PA; and Lee G. Wilke, University of Wisconsin Hospital and Clinics, Madison, WI.
Abstract
PURPOSE: The American College of Surgeons Oncology Group Z1071 trial reported a 12.6% false-negative rate (FNR) for sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in cN1 disease. Patients were not selected for surgery based on response, but a secondary end point was to determine whether axillary ultrasound (AUS) after NAC after fine-needle aspiration cytology can identify abnormal nodes and guide patient selection for SLN surgery. PATIENTS AND METHODS: Patients with T0-4, N1-2, M0 breast cancer underwent AUS after neoadjuvant chemotherapy. AUS images were centrally reviewed and classified as normal or suspicious lymph nodes. AUS findings were tested for association with pathologic nodal status and SLN FNR. The impact of AUS results to select patients for SLN surgery to reduce the FNR was assessed. RESULTS: Postchemotherapy AUS images were reviewed for 611 patients. One hundred thirty (71.8%) of 181 AUS-suspicious patients were node positive at surgery compared with 243 (56.5%) of 430 AUS-normal patients (P < .001). Patients with AUS-suspicious nodes had a greater number of positive nodes and greater metastasis size (P < .001). The SLN FNR was not different based on AUS results; however, using a strategy where only patients with normal AUS undergo SLN surgery would potentially reduce the FNR in Z1071 patients with ≥ two SLNs removed from 12.6% to 9.8% when preoperative AUS results are considered as part of SLN surgery. CONCLUSION: AUS is recommended after chemotherapy to guide axillary surgery. An FNR of 9.8% with the combination of AUS and SLN surgery would be acceptable for the adoption of SLN surgery for women with node-positive breast cancer treated with neoadjuvant chemotherapy.
PURPOSE: The American College of Surgeons Oncology Group Z1071 trial reported a 12.6% false-negative rate (FNR) for sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in cN1 disease. Patients were not selected for surgery based on response, but a secondary end point was to determine whether axillary ultrasound (AUS) after NAC after fine-needle aspiration cytology can identify abnormal nodes and guide patient selection for SLN surgery. PATIENTS AND METHODS: Patients with T0-4, N1-2, M0 breast cancer underwent AUS after neoadjuvant chemotherapy. AUS images were centrally reviewed and classified as normal or suspicious lymph nodes. AUS findings were tested for association with pathologic nodal status and SLN FNR. The impact of AUS results to select patients for SLN surgery to reduce the FNR was assessed. RESULTS: Postchemotherapy AUS images were reviewed for 611 patients. One hundred thirty (71.8%) of 181 AUS-suspicious patients were node positive at surgery compared with 243 (56.5%) of 430 AUS-normal patients (P < .001). Patients with AUS-suspicious nodes had a greater number of positive nodes and greater metastasis size (P < .001). The SLN FNR was not different based on AUS results; however, using a strategy where only patients with normal AUS undergo SLN surgery would potentially reduce the FNR in Z1071 patients with ≥ two SLNs removed from 12.6% to 9.8% when preoperative AUS results are considered as part of SLN surgery. CONCLUSION: AUS is recommended after chemotherapy to guide axillary surgery. An FNR of 9.8% with the combination of AUS and SLN surgery would be acceptable for the adoption of SLN surgery for women with node-positive breast cancer treated with neoadjuvant chemotherapy.
Authors: Savitri Krishnamurthy; Nour Sneige; Deepak G Bedi; Beth S Edieken; Bruno D Fornage; Henry M Kuerer; S Eva Singletary; Kelly K Hunt Journal: Cancer Date: 2002-09-01 Impact factor: 6.860
Authors: J Bonnema; A N van Geel; B van Ooijen; S P Mali; S L Tjiam; S C Henzen-Logmans; P I Schmitz; T Wiggers Journal: World J Surg Date: 1997 Mar-Apr Impact factor: 3.352
Authors: Eleftherios P Mamounas; Ann Brown; Stewart Anderson; Roy Smith; Thomas Julian; Barbara Miller; Harry D Bear; Christopher B Caldwell; Alonzo P Walker; Wendy M Mikkelson; Jay S Stauffer; Andre Robidoux; Heather Theoret; Atilla Soran; Atilla Sovan; Bernard Fisher; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Jean-Francois Boileau; Brigitte Poirier; Mark Basik; Claire M B Holloway; Louis Gaboury; Lucas Sideris; Sarkis Meterissian; Angel Arnaout; Muriel Brackstone; David R McCready; Stephen E Karp; Isabelle Trop; Andre Lisbona; Frances C Wright; Rami J Younan; Louise Provencher; Erica Patocskai; Atilla Omeroglu; Andre Robidoux Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell Journal: J Natl Cancer Inst Date: 2006-05-03 Impact factor: 13.506
Authors: Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt Journal: JAMA Date: 2013-10-09 Impact factor: 56.272
Authors: Lee Gravatt Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl G A Gabram; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano Journal: Ann Surg Oncol Date: 2006-03-02 Impact factor: 5.344
Authors: Rosalind P Candelaria; Roland L Bassett; William Fraser Symmans; Maheshwari Ramineni; Stacy L Moulder; Henry M Kuerer; Alastair M Thompson; Wei Tse Yang Journal: Oncologist Date: 2017-03-17
Authors: Abigail S Caudle; Henry M Kuerer; Savitri Krishnamurthy; Kyungmin Shin; Brian P Hobbs; Junsheng Ma; Elizabeth A Mittendorf; Ashley C Washington; Sarah M DeSnyder; Dalliah M Black; Kelly K Hunt; Wei T Yang Journal: Cancer Date: 2018-10-25 Impact factor: 6.860
Authors: Judy C Boughey; Karla V Ballman; Huong T Le-Petross; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; Eric C Feliberti; Kelly K Hunt Journal: Ann Surg Date: 2016-04 Impact factor: 12.969
Authors: Huong T Le-Petross; Linda M McCall; Kelly K Hunt; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Karla V Ballman; Judy C Boughey Journal: AJR Am J Roentgenol Date: 2018-01-30 Impact factor: 3.959